Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety
Articolo
Data di Pubblicazione:
2015
Abstract:
Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
ABATACEPT; EFFICACY; RHEUMATOID ARTHRITIS; SAFETY; SUBCUTANEOUS FORMULATION; THERAPY
Elenco autori:
Reggia, Rossella; Franceschini, Franco; Tincani, Angela; Cavazzana, Ilaria
Link alla scheda completa:
Pubblicato in: